NCT06835179View on ClinicalTrials.gov

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

May 31, 2027

Conditions
Unresectable Metastatic Colorectal CancerMicrosatellite Stable (MSS) Colorectal Cancer (CRC)RAS-mutant Colorectal Cancer
Interventions
RADIATION

SBRT

SBRT short course radiotherapy (total dose 30-60 Gy, completed in 3-5 sessions)

DRUG

PD-1 Inhibitors

Tislelizumab (200mg on day 1)

DRUG

CapeOX + bevacizumab

intravenous administration of bevacizumab (7.5mg/kg on day 1), oxaliplatin (135mg/m² on day 1), as well as oral capecitabine (1g/m² twice daily from day 1 to day 14)

All Listed Sponsors
lead

The First Affiliated Hospital with Nanjing Medical University

OTHER